tenet hospital healthcare for-profit lobbying medicaid emergency fraud site-neutral 340B USPI ambulatory
related: Hospital Corporation of America - HCA Blue Cross Blue Shield Association PhRMA Anthem - Elevance Health PBM Industry Bloc - OptumRx, CVS Caremark, Express Scripts
Who They Are
Tenet Healthcare Corporation (NYSE: THC). One of the largest for-profit hospital chains in the United States, headquartered in Dallas, Texas. As of 2024, Tenet operates approximately 60 hospitals and over 550 outpatient centers across 13 states through its subsidiary United Surgical Partners International (USPI), generating $20.7 billion in annual revenue (2024). The company employs approximately 100,000 people.
Tenet’s political operation runs through the Tenet Healthcare Corporation Political Action Committee (FEC ID: C00119354), registered since January 1980, which raised $443,374 in the 2024 cycle. The company spent $2.2 million on federal lobbying in 2024 and $2.36 million in 2023 — targeting Medicaid reimbursement rates, opposition to site-neutral payment reform, 340B drug pricing protections, and the Outpatient Surgery Quality and Access Act (H.R.972/S.312). Half of Tenet’s 12 registered lobbyists in 2024 previously held government jobs — a 50% revolving door rate.
Tenet’s business model converts healthcare into shareholder returns by optimizing the revenue cycle: acquiring hospitals in markets with favorable payer mix (more insured patients), maximizing Medicare/Medicaid reimbursement through billing and coding optimization, and reducing costs through labor management and service standardization. Since 2020, Tenet has aggressively pivoted toward ambulatory surgery centers (ASCs) through USPI — the largest ambulatory platform in the country with 535+ facilities — while divesting hospital assets: nine hospitals sold in 2024 alone (to Novant Health, UCI Health, and Adventist Health) for a combined $3 billion in after-tax proceeds.
Money
Tenet’s pivot from hospitals to ambulatory surgery centers is not a retreat from the for-profit healthcare model — it is its optimization. ASCs generate higher margins than inpatient hospitals while requiring less capital and less regulatory exposure. Tenet’s $2.2M annual lobbying investment protects the reimbursement structures that make both business lines profitable: opposing site-neutral payments that would equalize Medicare rates between hospital outpatient departments and ASCs, defending 340B drug discount program access for hospital pharmacies, and fighting Medicaid DSH cuts that would reduce safety-net hospital funding. The political investment protects revenue streams worth $20+ billion per year.
What They Want
Tenet’s federal lobbying targets four overlapping policy areas, all designed to protect the revenue structures that underpin for-profit hospital economics:
Site-neutral payment opposition: Tenet lobbied heavily on H.R.972 (Outpatient Surgery Quality and Access Act of 2023) — the bill most frequently lobbied by Tenet in the 118th Congress (4 quarterly reports). This legislation would equalize Medicare payment rates for ambulatory surgery centers relative to hospital outpatient departments. Tenet’s lobbying position is strategically complex: the company operates both hospital outpatient departments (which benefit from higher Medicare rates under the current system) and ambulatory surgery centers through USPI (which would benefit from rate equalization). Tenet’s lobbying protects whichever rate structure maximizes its revenue in each market.
Medicaid DSH funding: Tenet operates safety-net hospitals in multiple states that depend on Disproportionate Share Hospital (DSH) payments — federal supplemental payments to hospitals serving high proportions of Medicaid and uninsured patients. DSH cuts totaling $24 billion were repeatedly delayed by Congress; Tenet lobbies to maintain these payments while simultaneously divesting the hospitals most dependent on them.
340B drug pricing protections: Tenet hospitals participate in the 340B drug discount program, which allows qualifying hospitals to purchase outpatient drugs at steep discounts (25-50% below market) while billing Medicare and private insurers at full price. The spread between acquisition cost and reimbursement generates significant pharmacy revenue. Tenet lobbies to maintain 340B eligibility and to oppose CMS proposals to reduce 340B hospital reimbursement rates.
Medicare for All opposition: Between July 2018 and June 2019, Tenet donated nearly $630,000 to the Partnership for America’s Health Care Future — the industry coalition created by hospitals, insurers, and pharma companies to oppose Medicare for All and any single-payer legislation. Single-payer would eliminate the private insurance reimbursement rates that generate Tenet’s highest margins.
Contradiction
Tenet simultaneously lobbies to protect Medicaid DSH payments (arguing its hospitals serve the uninsured poor) while divesting the very hospitals most dependent on those payments and pivoting to ambulatory surgery centers that serve commercially insured patients. The company’s political message — that it needs government funding to serve vulnerable populations — is contradicted by its corporate strategy of exiting the markets where those populations live.
Who They Fund
Tenet’s PAC contributions are bipartisan by design — the company funds whoever controls the committees that regulate hospital payments, regardless of party. In the 2024 cycle ($443,374 total):
Top recipients (2024 cycle):
- Kamala Harris (D-PRES): $59,519 (individual contributions from Tenet employees)
- Donald Trump (R-PRES): $28,678 (individual contributions)
- Republican National Committee: $19,327
- Colin Allred (D-TX32): $18,530 — Tenet is headquartered in Dallas; Allred represented the Dallas area
- House Majority PAC: $15,000 (PAC contribution)
- Elissa Slotkin (D-MI07): $12,233
- Ted Cruz (R-TXS2): $11,751 ($5,000 PAC + $6,751 individual)
- Bluegrass Committee (Mitch McConnell leadership PAC): $10,000
Contribution pattern: 78% of funds came from individual employee contributions; 22% from the PAC itself. 68% went to candidates, 16% to party committees, 6% to leadership PACs. The bipartisan split reflects Tenet’s regulatory exposure: Medicare and Medicaid payment policies are set by CMS under executive branch authority and by congressional committees under both parties.
Lobbying firms: Tenet retained 12 registered lobbyists in 2024 (6 with revolving door backgrounds — former government employees). The company’s most frequently lobbied bills in the 118th Congress were H.R.972 and S.312 (Outpatient Surgery Quality and Access Act) and S.2840 (Bipartisan Primary Care and Health Workforce Act).
Donation-to-Policy Timeline
| Date | Recipient/Target | Amount | Policy Return | Time Gap |
|---|---|---|---|---|
| 2006 | DOJ settlement — Medicare outlier fraud | $900M settlement | Tenet continued operating; no debarment from federal programs despite systematic Medicare fraud | N/A — penalty |
| 2016 | DOJ settlement — Clinica de la Mama kickback scheme | $513M ($368M civil + $145M criminal) | Two subsidiaries pled guilty; Georgia recovered $100M+; Tenet continued operating and receiving federal funds | N/A — penalty |
| 2018–2019 | Partnership for America’s Health Care Future | ~$630,000 | Coalition ran national ad campaign opposing Medicare for All; no single-payer legislation advanced past committee | 6–12 months |
| 2022 | Federal lobbying (Congress, CMS) | $2.33M lobbying spend | Medicaid DSH cuts delayed again; site-neutral payment reforms did not advance in 117th Congress | 0–12 months |
| 2023 | Federal lobbying — H.R.972/S.312, S.2840 | $2.36M lobbying spend | Outpatient Surgery Quality and Access Act did not pass; favorable status quo maintained for hospital outpatient reimbursement rates | Ongoing |
| 2024 | Federal lobbying + PAC contributions | $2.2M lobbying + $443K PAC | Site-neutral payment reform stalled in 118th Congress; 340B hospital reimbursement maintained; Tenet completed $3B in hospital divestitures while lobbying to protect hospital payment structures | 0–12 months |
Money
The timeline reveals a corporation that has paid over $1.4 billion in fraud settlements to the federal government while simultaneously spending $2-3 million per year lobbying that same government to maintain the reimbursement structures that generate its revenue. The fraud settlements — for Medicare outlier gaming (2006), Medicaid kickbacks (2016), unnecessary cardiac monitor implants ($1.41M, 2015) — demonstrate systematic exploitation of the payment systems Tenet lobbies to protect. The political investment is not separate from the fraud history; both are expressions of the same business model: extract maximum revenue from government healthcare programs through whatever combination of legal lobbying and illegal billing produces the highest returns.
What They’ve Gotten
Policy wins (what Tenet’s lobbying protected):
- Medicaid DSH cuts repeatedly delayed — $24 billion in scheduled cuts have been postponed by Congress multiple times, preserving supplemental payments to Tenet’s safety-net hospitals
- Site-neutral payment reform stalled — CBO estimates site-neutral payments would save Medicare $157 billion; the hospital lobby (including Tenet) has prevented comprehensive implementation
- 340B drug discount program maintained — hospital pharmacy spread between 340B acquisition costs and full-price reimbursement continues to generate significant revenue
- Medicare for All blocked — the Partnership for America’s Health Care Future coalition, to which Tenet contributed $630K, successfully prevented single-payer legislation from advancing
Corporate outcomes (what the political protection enabled):
- Tenet completed its pivot to ambulatory surgery centers: USPI now operates 535+ facilities generating higher margins than inpatient hospitals
- Divested nine hospitals in 2024 for $3 billion in after-tax proceeds while lobbying to maintain the payment structures those hospitals depended on
- Stock price increased from ~$20 (2020) to over $150 (2024) as the ASC pivot generated returns
- Despite $1.4 billion+ in cumulative fraud settlements, Tenet was never debarred from Medicare or Medicaid — the company continued receiving billions in federal healthcare payments
What didn’t happen:
- No debarment from federal programs despite serial fraud — the DOJ settlements included criminal guilty pleas by subsidiaries but no systemic consequences for the parent company’s federal program participation
- No comprehensive site-neutral payment reform — the CBO-estimated $157 billion in Medicare savings remains unrealized
- No structural reform to the for-profit hospital billing model that Tenet’s fraud history demonstrates is prone to systematic exploitation
Class Analysis
Tenet Healthcare is a textbook case of healthcare financialization — the conversion of a public good (medical care) into a financial instrument optimized for shareholder returns. The company’s political operation exists to protect the regulatory and payment structures that make this conversion profitable.
The structural function operates on three levels:
Level 1 — Revenue extraction: Tenet’s business model depends on the gap between the cost of delivering care and the price the government and private insurers pay. Every lobbying dollar protects this gap: opposing site-neutral payments maintains the higher hospital outpatient rates; defending 340B preserves the pharmacy pricing spread; blocking DSH cuts maintains supplemental Medicaid payments. The $2-3 million annual lobbying investment protects $20+ billion in annual revenue.
Level 2 — Fraud as business strategy: Tenet’s $1.4 billion+ in fraud settlements are not aberrations — they are the predictable result of a business model that incentivizes maximizing reimbursement from government programs. The 2006 Medicare outlier scheme ($900M), the 2016 Clinica de la Mama kickback operation ($513M), and the 2015 unnecessary cardiac monitor implants ($1.41M) all exploited the same payment systems Tenet lobbies to maintain. The settlements function as a cost of doing business: Tenet pays a fraction of what it extracted, continues operating, and returns to lobbying for the same payment structures.
Level 3 — Portfolio optimization as political arbitrage: Tenet’s simultaneous strategy of lobbying to protect hospital payment structures while divesting hospitals and pivoting to ASCs represents political arbitrage. The company lobbies to maintain the reimbursement environment that maximizes the sale price of its hospital assets, then reinvests the proceeds in ambulatory surgery centers where margins are higher and regulatory exposure is lower. The political operation protects the value of assets Tenet is selling — the buyers inherit the lobbying dependency.
The bipartisan contribution pattern confirms the structural analysis: Tenet funds Democrats and Republicans in roughly equal measure because Medicare and Medicaid payment policy is determined by whichever party controls CMS and the relevant congressional committees. The company does not invest in ideology — it invests in access to the regulatory apparatus that determines its revenue.
Sources
- OpenSecrets: Tenet Healthcare organizational profile (Tier 1)
- OpenSecrets: Tenet Healthcare lobbying profile (Tier 1)
- FEC: Tenet Healthcare Corporation Political Action Committee (C00119354) (Tier 1)
- DOJ: Tenet Healthcare to Pay U.S. More Than $900 Million (2006) (Tier 1)
- DOJ: Hospital Chain Will Pay Over $513 Million for Defrauding the United States (2016) (Tier 1)
- Georgia AG: Landmark Kickback Settlement With Tenet Healthcare — Over $100 Million Returned (Tier 1)
- Congress.gov: H.R.972 — Outpatient Surgery Quality and Access Act of 2023 (Tier 1)
- Becker’s Hospital Review: Tenet Spends $630K to Derail ‘Medicare for All’ (Tier 2)
- Ballotpedia: Tenet Healthcare (Tier 3)
- Tenet Healthcare: Disclosure of Political Expenditures (Tier 1)
content-readiness:: developed